Publications by authors named "Ray F Ebert"

Claim this Profile
R
Recommendations for nomenclature and definition of cell products intended for human cardiovascular use.
Doris A Taylor, Lourdes Chacon-Alberty, Luiz C Sampaio, Mariana Gonzalez Del Hierro, Emerson C Perin, Ray F Ebert

Cardiovasc Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.
Roberto Bolli, Raul D Mitrani, Joshua M Hare, Carl J Pepine, Emerson C Perin, Ray F Ebert

Eur J Heart Fail· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial.
Roberto Bolli, Emerson C Perin, James T Willerson, Phillip C Yang, Jay H Traverse, Ray F Ebert

JACC CardioOncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.
Roberto Bolli, Joshua M Hare, Timothy D Henry, Carrie G Lenneman, Keith L March, Ray F Ebert

Am Heart J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit Cardiac Stem Cells As Regenerative Therapy for Heart Failure).
Roberto Bolli, Joshua M Hare, Keith L March, Carl J Pepine, James T Willerson, Ray F Ebert

Circ Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis.
Jay H Traverse, Timothy D Henry, Carl J Pepine, James T Willerson, Atul Chugh, Ray F Ebert

Circ Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.
Doris A Taylor, Emerson C Perin, James T Willerson, Claudia Zierold, Micheline Resende, Ray F Ebert

Cell Transplant· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).
Emerson C Perin, Michael P Murphy, Keith L March, Roberto Bolli, John Loughran, Ray F Ebert

Circulation· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cells" (CCTRN PACE) study.
Bharath Ambale Venkatesh, Victor Nauffal, Chikara Noda, Tomoki Fujii, Phillip C Yang, Ray F Ebert

Am Heart J· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, Jay H Traverse, Timothy D Henry, Ray F Ebert

Am Heart J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NHLBI SMARTT Program: A Novel Approach to Facilitate Translational Research for Heart, Lung and Blood Diseases.
Ray F Ebert, Narasimhan S Danthi, Marc F Charette, Manjit Hanspal, Traci H Mondoro

Circ Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease.
Samuel Golpanian, Ivonne H Schulman, Ray F Ebert, Alan W Heldman, Darcy L DiFede

Stem Cells Transl Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.
Robert C Schutt, Barry H Trachtenberg, John P Cooke, Jay H Traverse, Timothy D Henry, Ray F Ebert

Circ Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.
Emerson C Perin, Michael Murphy, John P Cooke, Lem Moyé, Timothy D Henry, Ray F Ebert

Am Heart J· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.
Christopher R Cogle, Elizabeth Wise, Amy M Meacham, Claudia Zierold, Jay H Traverse, Ray F Ebert

Circ Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network.
Robert D Simari, Carl J Pepine, Jay H Traverse, Timothy D Henry, Roberto Bolli, Ray F Ebert

Circ Res· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.
Jay H Traverse, Timothy D Henry, Carl J Pepine, James T Willerson, David X M Zhao, Ray F Ebert

JAMA· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
Emerson C Perin, James T Willerson, Carl J Pepine, Timothy D Henry, Stephen G Ellis, Ray F Ebert

JAMA· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
Jay H Traverse, Timothy D Henry, Stephen G Ellis, Carl J Pepine, James T Willerson, Ray F Ebert

JAMA· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis